• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Aspirin therapy combined with warfarin without clinical indication associated with increased bleeding

byJalal EbrahimandAnees Daud
March 11, 2019
in Cardiology, Chronic Disease, Emergency, Gastroenterology, Public Health
Reading Time: 3 mins read
Aspirin therapy linked to fewer cases of preeclampsia
Share on FacebookShare on Twitter

1. In this retrospective cohort study conducted in Michigan, aspirin therapy combined with warfarin for patients without a clinical indication was associated with increased rates of major bleeding, emergency visits for bleeding, and hospital admissions for bleeding.

2. Among these patients, there was no difference in rates of thrombosis or mortality.

Evidence Rating Level: 2 (Good)

Study Rundown: Warfarin and aspirin are two of the most widely used medications in North America, however rates of concomitant use without a clear indication are not clear. Apart from patients with recent acute coronary syndrome or mechanical heart valves, there are few clinical indications for this concomitant use. This was a retrospective cohort study looking at propensity matched pairs of patients with atrial fibrillation or venous thromboembolism started on warfarin between 2010 and 2017 in Michigan. The study found that use of aspirin with coumadin without a clinical indication for the aspirin was associated with more overall and major bleeding, more hospital admission and emergency department visits for bleeding. There was no difference in the rates of thrombosis or overall mortality.

The strengths of the study include the large sample size, propensity matching, long follow up, and documentation of time spent in therapeutic INR range. Weaknesses of the study include the retrospective nature of the study and reliance on chart review to identify clinical indications.

Click to read the study in JAMA Internal Medicine

RELATED REPORTS

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

Antithrombotic agents may be effective in preventing migraine in patients with patent foramen ovale

Adjunctive prednisolone does not reduce coronary artery lesions in Kawasaki disease

Relevant Reading: Combined Aspirin–Oral Anticoagulant Therapy Compared With Oral Anticoagulant Therapy Alone Among Patients at Risk for Cardiovascular Disease: A Meta-analysis of Randomized Trials

In-Depth [retrospective cohort]: This was a retrospective cohort study of 6359 patients started on warfarin between January 2010 and December 2016 for atrial fibrillation or venous thromboembolism. Follow up occurred until December 2017.  Exclusion criteria included receipt of direct oral anticoagulants, myocardial infarction within six months of warfarin initiation, and history of heart valve replacement (mechanical or bioprosthetic). Patients were recruited through the Blue Cross Blue Shield of Michigan–sponsored Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry. Data was collected on patient demographics, comorbidities, thrombosis and bleeding risk factors, and medications. Primary bleeding outcomes included any patient reported bleeding, major bleeding (as defined by International Society on thrombosis and hemostasis), emergency department visits for bleeding, and hospitalizations for bleeding. Primary thrombosis outcomes included ischemic strokes, transient ischemic attacks (TIAs), acute coronary syndrome/myocardial infarctions (ACS/MI), emergency room visits for thrombosis, and hospitalizations for thrombosis. Mortality data was also collected.

There were 1844 propensity matched pairs (3688 total patients) of patients on warfarin alone versus warfarin with aspirin. 2453 (37.5%) were receiving aspirin without clear indication. In propensity matched groups, patients on aspirin and warfarin had more overall bleeding events (cumulative incidence at one year 26.0% [95% CI 23.8%-28.3%] vs 20.3% [95% CI 18.3%-22.3%] p<0.001), more major bleeding (cumulative incidence at one year 5.7% [95% CI 4.6%-7.1%] vs 3.3% [95% CI 2.4%-4.3%] p<.001), more emergency room visits for bleeding (cumulative incidence at one year 13.3% [95% CI 11.6%-15.1%] vs 9.8% [95% CI 8.4%-11.4.%] p<.001), and more hospitalizations for bleeding (cumulative incidence at one year 8.1% [95% CI 6.8%-9.6%] vs 5.2% [95% CI 4.1%-6.4%] p<.001). There was no difference in thrombotic events for those on aspirin and warfarin (cumulative incidence at one year 2.3% [95% CI 1.6%-3.1%] vs 2.7% [95% CI 2.0%-3.6%] p=0.40). There was no difference in mortality for those on aspirin and warfarin (cumulative incidence at one year 4.4% [95% CI 3.4%-5.6%] vs 3.7% [95% CI 2.8%-4.8%] p=0.34).

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: aspirinmajor bleedingwarfarin
Previous Post

Sudden infant death risk rises linearly with amount smoked by mothers

Next Post

Behavioral intervention produces sustained change in physical activity in type 2 diabetes patients

RelatedReports

Nephrology

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

September 9, 2026
Prochlorperazine for migraine may lower likelihood of ED return
Chronic Disease

Antithrombotic agents may be effective in preventing migraine in patients with patent foramen ovale

August 7, 2026
Differences in sudden unexpected infant death rates reported between states
Cardiology

Adjunctive prednisolone does not reduce coronary artery lesions in Kawasaki disease

April 15, 2026
Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Cardiology

Clopidogrel monotherapy is superior to aspirin for secondary prevention in coronary artery disease

October 30, 2025
Next Post
Sleep duration inversely related to childhood type 2 diabetes risk makers

Behavioral intervention produces sustained change in physical activity in type 2 diabetes patients

Transthoracic echocardiography can rule out endocarditis in low-risk bacteremic patients

2 Minute Medicine Rewind March 11, 2019

Thyroidectomy more effective than medication for Hashimoto disease with persisting symptoms

Thyroidectomy more effective than medication for Hashimoto disease with persisting symptoms

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Brepocitinib becomes first oral therapy approved for adult dermatomyositis
  • An ultrasound-guided percutaneous method of vagal nerve stimulation may be effective for refractory chronic pain
  • Daraxonrasib extends survival in metastatic pancreatic cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.